To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
We believe in accelerating discovery processes to bring solutions to patients through innovative science driven by co-creation.
Externally Sponsored Research (ESR) can lead to meaningful advances in disease understanding and treatment.
argenx supports interventional and observational Investigator-Initiated Studies (IIS), which are conducted by an external third party that assumes regulatory and legal responsibility for development, conduct, and oversight of the study.
Innovation is a cultural pillar of argenx, which drives us to unearth critical breakthroughs in immunology medicine with every step we take toward improving patient outcomes.
argenx values open collaboration and partnership in the spirit of creating novel therapies and treatment options. As part of this commitment, argenx will consider proposals within a wide range of focus.
To learn about our current areas of interest in detail, please download our Investigator-Initiated Studies Guide or submit an inquiry at esr@argenx.com or fill out the form below.
Everything we do should improve the lives of patients and caregivers.
Our science and research efforts should seek to deliver real-world impact for both physicians and patients.
We adhere to a strict ethical standard and only look to co-create with those who prioritize transparency and compliance.
argenx wants to deliver new and novel therapies that disrupt longstanding gaps in the standard of care.
Clinical Research Collaboration is similar to IIS research in that the external third party assumes regulatory and legal responsibility for development, conduct, and oversight of the study. Unlike with IIS, argenx can initiate research and co-create with investigators in service of developing and executing innovative study designs and move the science forward together.
Please fill out the form, tell us how we can help, and we will get in touch with you shortly by email or phone.
Inquiries and research proposals that are not an ESR can be sent to BD@argenx.com.
We work alongside researchers, clinicians, and universities to accelerate discoveries. Together, we’re transforming care for people with long-ignored diseases.
Decisions for grants are made through a formal grant review and decision-making process. The Grant Review Committee assesses and approves applications based upon need, design, scientific rigor, independence, and compliance. Approvals depend on available funding, the volume of requests, and alignment with argenx’s areas of interest.
At argenx, every piece of the innovation story connects. See where it leads next.
See how IIP-born assets move forward with the right partners.
As broad as it is deep. Explore every program we’re advancing in immunology.
The science and data behind our first-in-class FcRn-targeting antibody for severe autoimmune diseases.